Success Metrics

Clinical Success Rate
71.4%

Based on 40 completed trials

Completion Rate
71%(40/56)
Active Trials
9(11%)
Results Posted
48%(19 trials)
Terminated
16(19%)

Phase Distribution

Ph phase_2
33
40%
Ph not_applicable
2
2%
Ph phase_4
1
1%
Ph early_phase_1
3
4%
Ph phase_1
40
48%
Ph phase_3
1
1%

Phase Distribution

43

Early Stage

33

Mid Stage

2

Late Stage

Phase Distribution80 total trials
Early Phase 1First-in-human
3(3.8%)
Phase 1Safety & dosage
40(50.0%)
Phase 2Efficacy & side effects
33(41.3%)
Phase 3Large-scale testing
1(1.3%)
Phase 4Post-market surveillance
1(1.3%)
N/ANon-phased studies
2(2.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

65.6%

40 of 61 finished

Non-Completion Rate

34.4%

21 ended early

Currently Active

9

trials recruiting

Total Trials

83

all time

Status Distribution
Active(12)
Completed(40)
Terminated(21)
Other(10)

Detailed Status

Completed40
Terminated16
unknown8
Recruiting6
Withdrawn5
Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials
83
Active
9
Success Rate
71.4%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (3.8%)
Phase 140 (50.0%)
Phase 233 (41.3%)
Phase 31 (1.3%)
Phase 41 (1.3%)
N/A2 (2.5%)

Trials by Status

terminated1619%
recruiting67%
completed4048%
unknown810%
not_yet_recruiting34%
withdrawn56%
active_not_recruiting34%
suspended22%

Recent Activity

Clinical Trials (83)

Showing 20 of 83 trialsScroll for more
NCT06158828Phase 1

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Recruiting
NCT02557074Phase 3

TREg Activation in the Treatment of the PELADE (Alopecia Areata)

Completed
NCT04629729Phase 1

FT819 in Subjects With B-cell Malignancies

Active Not Recruiting
NCT04347616Phase 1

Natural Killer-cell Therapy for Acute Myeloid Leukemia

Terminated
NCT03666000Phase 1

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT03474497Phase 1

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Active Not Recruiting
NCT05357027Phase 1

HPV16 E6 TCR T Cells for Cervical Carcinoma

Terminated
NCT06255028Phase 1

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

Active Not Recruiting
NCT04155710Phase 1

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

Completed
NCT05336409Phase 1

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Terminated
NCT03039673Phase 2

MIROCALS: Modifying Immune Response and OutComes in ALS

Completed
NCT05400122Phase 1

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

Suspended
NCT05881525Phase 1

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

Recruiting
NCT04625205Phase 1

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

Terminated
NCT06302062Phase 1

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

Recruiting
NCT03175679Phase 1

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Completed
NCT02919644Phase 2

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

Recruiting
NCT01898793Phase 1

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Terminated
NCT00968760Phase 1

CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies

Completed
NCT06107894Phase 1

TIL Therapy for Patients With Advanced Solid Tumors

Not Yet Recruiting

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
83